Hennion & Walsh Asset Management Inc. Acquires Shares of 95,935 Indivior PLC (NASDAQ:INDV)

Hennion & Walsh Asset Management Inc. bought a new position in shares of Indivior PLC (NASDAQ:INDVFree Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 95,935 shares of the company’s stock, valued at approximately $1,192,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Geode Capital Management LLC increased its position in Indivior by 7.7% in the 3rd quarter. Geode Capital Management LLC now owns 132,239 shares of the company’s stock valued at $1,289,000 after acquiring an additional 9,500 shares in the last quarter. Public Employees Retirement System of Ohio acquired a new stake in shares of Indivior in the third quarter valued at approximately $294,000. XTX Topco Ltd raised its position in Indivior by 763.4% in the 3rd quarter. XTX Topco Ltd now owns 133,194 shares of the company’s stock worth $1,299,000 after purchasing an additional 117,767 shares during the last quarter. Krensavage Asset Management LLC acquired a new position in Indivior during the 3rd quarter worth $6,843,000. Finally, Jane Street Group LLC bought a new position in Indivior in the 3rd quarter valued at $180,000. 60.33% of the stock is currently owned by institutional investors and hedge funds.

Indivior Stock Down 0.1 %

Shares of Indivior stock opened at $11.65 on Friday. The business has a fifty day simple moving average of $11.46 and a 200 day simple moving average of $11.07. The stock has a market cap of $1.61 billion, a PE ratio of -291.18 and a beta of 0.74. Indivior PLC has a 12 month low of $7.33 and a 12 month high of $23.22.

Indivior (NASDAQ:INDVGet Free Report) last released its quarterly earnings data on Thursday, October 24th. The company reported $0.54 earnings per share for the quarter, topping the consensus estimate of $0.39 by $0.15. Indivior had a negative net margin of 0.17% and a negative return on equity of 351.08%. The business had revenue of $307.00 million for the quarter, compared to analyst estimates of $302.25 million. Analysts expect that Indivior PLC will post 1.62 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

INDV has been the subject of a number of recent research reports. Craig Hallum dropped their target price on Indivior from $20.00 to $16.00 and set a “buy” rating for the company in a research report on Friday, October 11th. Piper Sandler reiterated an “overweight” rating and set a $16.00 price target (up previously from $15.00) on shares of Indivior in a research report on Friday, October 25th.

View Our Latest Stock Report on INDV

Indivior Profile

(Free Report)

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.

Featured Articles

Want to see what other hedge funds are holding INDV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Indivior PLC (NASDAQ:INDVFree Report).

Institutional Ownership by Quarter for Indivior (NASDAQ:INDV)

Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.